Skip to content
‹ Back to IndustriesSciences

Launch Sites, Rocket Tech, Tourism: Drivers of the Space Economy Making Headway in 2024

Tourism, increasing commercialization, technology innovations, and sustainable operations will all play a critical role in the 2024 space economy. The space industry witnessed remarkable achievements and ambitious plans in 2023, setting the stage for an even more dynamic 2024. A record-breaking 207 successful orbital launches in 2023, with the U.S. leading the charge with…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · · AstroscaleDaniel LitwinDave HebertExperts Talk
Share

Key takeaways

01

Tourism, increasing commercialization, technology innovations, and sustainable operations will all play a critical role in the 2024 space economy.

02

The space industry witnessed remarkable achievements and ambitious plans in 2023, setting the stage for an even more dynamic 2024.

03

A record-breaking 207 successful orbital launches in 2023, with the U.S.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Tourism, increasing commercialization, technology innovations, and sustainable operations will all play a critical role in the 2024 space economy.

The space industry witnessed remarkable achievements and ambitious plans in 2023, setting the stage for an even more dynamic 2024. A record-breaking 207 successful orbital launches in 2023, with the U.S. leading the charge with 108 launches, broke the Soviet Union’s long-standing record. SpaceX was a major contributor, responsible for nearly half of these launches, and also broke its record for rocket reuse. The year also saw significant advancements in commercial space launches. Phantom Space and Vaya Space signed a revolutionary agreement to operate simultaneously from a single launch complex, showcasing a novel approach to maximizing limited launch-site availability.

The space tourism market is on an explosive growth trajectory, expected to grow at a compound annual growth rate (CAGR) of 49.9% from 2024 to 2030, driven by technological advancements and increasing interest from high-net-worth individuals. Meanwhile, the global space sector is keenly watching the development of next generation launch vehicles and lunar landers and the increasing involvement of private companies in space exploration. The competition between the U.S. and China is intensifying, with both nations investing heavily in space technology and exploration. This rivalry, along with the evolving role of NASA vis-à-vis the private sector, the development of new launch vehicles, and the dynamics of space financing and business evolution, are shaping the future of space exploration and commercialization.

Which of these trends are moving beyond the headlines to impact the space economy in 2024 and beyond? “Experts Talk,” presented by MarketScale brings together a panel of space industry veterans. Joining host Daniel J Litwin, the Voice of B2B, are Rick Ward, the Founder & CTO of OrbitsEdge; Dave Hebert, the Vice President of Global Marketing & Communications at Astroscale U.S.; and Kevin Lowdermilk, the CEO at Vaya Space. Together, they break down the top sectors of the space economy set to drive growth in 2024, offering insights into the future of space exploration and its commercial potential.

Key points of discussion include:

  • The increasing commercialization of space and its implications for global connectivity and technological innovation
  • The role of satellite technology in enhancing global communication networks, with a focus on the integration of satellite and terrestrial systems
  • The burgeoning field of space tourism and its potential to democratize access to space, alongside the challenges of ensuring safety and sustainability
  • The critical importance of sustainable space operations, including debris management and the development of in-space servicing and manufacturing capabilities

Rick Ward is a pioneer in applying edge computing to space, enhancing data processing in orbit through his work at OrbitsEdge. His innovative approach combines aerospace engineering expertise with a vision for technology-driven space exploration, making him a leading figure in the space economy’s evolution.

Dave Hebert plays a crucial role at Astroscale U.S., Inc., focusing on space debris mitigation and on-orbit servicing. With extensive experience in space policy and communications, Dave advocates for sustainable space practices, contributing significantly to the industry’s future direction.

Kevin Lowdermilk leads Vaya Space, focusing on advancing space travel through innovative propulsion technologies—his engineering and business background drives Vaya Space’s mission to provide efficient and sustainable space access.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

PharmaLogic is buying Lantheus' contract manufacturing unit and Springfield, New Jersey radiopharmaceutical plant, plus a long-term deal to make lutetium Lu 177 dotatate for Lantheus. Radioligand developers looking for capacity should ask how much of the plant's capacity is still open.

  • 01A long-term supply contract attached to a plant sale could help keep costly hot-cell capacity in use. According to Grand View Research, committed supply agreements are among the tools that help providers align capital spending with customer development milestones.
  • 02Radioligand developers evaluating PharmaLogic's Agilera unit should ask how much Springfield capacity the lutetium Lu 177 dotatate contract will take up and how much is left for new programs.
  • 03Two pending transactions shape what to watch next: regulatory review and closing conditions for the PharmaLogic purchase, and Curium’s August offer of upward of $8 billion for Lantheus, which is still closing.

Nov 18, 2026

Merck KGaA moves Rapid Micro’s Growth Direct from distribution to ownership for QC labs

Merck KGaA moves Rapid Micro’s Growth Direct from distribution to ownership for QC labs

Merck KGaA agreed to buy Rapid Micro Biosystems, maker of the Growth Direct microbial testing platform, for $0.75 per share in cash. The deal turns a 2025 distribution partnership into ownership. Growth Direct instruments, consumables and software would then come from the company that already sells QC products to pharma labs, pending a December 2026 close.

  • 01Growth Direct shifts from a Merck-distributed product, under a February 2025 agreement, to a Merck-owned one inside a QC portfolio that spans environmental monitoring, in-process and release testing.
  • 02For labs that already run Growth Direct alongside MilliporeSigma QC products, the useful question is how the platform's digital sample records will connect to the rest of that workflow after close.
  • 03The next date to watch is the Schedule TO filing that opens the tender offer; closing targeted for December 2026 requires a majority of Rapid Micro’s voting shares to be tendered.

Nov 17, 2026

SR-Tiget gene therapy families average six months in Milan, with years of follow-up testing

SR-Tiget gene therapy families average six months in Milan, with years of follow-up testing

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, the programme logged 133 follow-up visits against 17 treatments; with roughly 15 years of twice-yearly checkups per patient, the follow-up load is likely to keep growing even if new treatments stay flat.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03A practical question for gene therapy services: who alerts the lab when a child’s fever delays a blood draw? At SR-Tiget, research nurses manage the patient schedule and coordinate sample timing with the lab.

Nov 16, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512